Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-so-familiar routine of meetings, calls, and deadlines has predictably returned. To cope, yes, we are firing up the trusty coffee kettle to brew some cups of stimulation. We are starting off with blueberry cobbler. Feel free to join us or, if you prefer, grab a bottle of water. Meanwhile, here is the usual menu of interesting items. Hope your day goes well and please do keep in touch …

China has granted conditional approval to its first self-developed treatment for Alzheimer’s disease, a move that may point to revived opportunities in a therapeutic area where drug makers have burned billions of dollars without yielding a validated new drug, Reuters explains. Oligomannate, which uses extract from marine brown algae as raw material, received a conditional green light to treat mild- to moderate- level Alzheimer’s. China is fast-tracking approval for innovative drugs at home in a bid to offer more and cheaper options to patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!